|Videos|August 24, 2022
Future Perspectives in Biomarker Identification and Testing in MM
Author(s)Shaji Kumar, MD, Jonathan L. Kaufman, MD
Shaji Kumar, MD and Jonathan Kaufman, MD, discuss unmet needs in the multiple myeloma treatment landscape and share their insights on testing for biomarkers.
Episodes in this series
Related to this article
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.
Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.
Teclistamab-based induction generated a 91.8% MRD-negative complete response rate with a manageable safety profile in multiple myeloma.
The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.
An analysis of 12 randomized trials validated MRD-negative CR as a surrogate for PFS in earlier-line relapsed/refractory multiple myeloma.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.
Trending on OncLive
1
FDA Approves Rusfertide for Polycythemia Vera
2
The OncFive: Top Oncology Articles for the Week of 8/23
3
DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer
4
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
5